AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaStocks · News reference
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 6:24 AM
- Checked
- Aug 27, 2026, 6:24 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-incSMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research